Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SIGA vs ESPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ESPR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

ESPR Overall Winner 6-Pillar Tally: SIGA 1 – 5 ESPR Matrix Metrics: SIGA 3 – 7 ESPR

As of Nov 20, 2026, Esperion Therapeutics, Inc. (ESPR) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SIGA carries a Unified Composite Score of 46.2/100 (HOLD) at $2.40 (2.3x Forward P/E, -14.2% operating margin), whereas ESPR carries 60.0/100 (BUY) at $3.18 (10.9x Forward P/E, -8.2% operating margin).

  • Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.0); meanwhile ESPR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SIGA vs ESPR
SIGA NASDAQ
SIGA Technologies Inc.
Pharmaceutical Preparations
$2.40
-9.43% 1D
Market Cap $188.3M
TTM Revenue $52M
Forward P/E 2.3x
Beta / 30D Vol 0.90β · 74% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 33.0 Fund 53.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.2%), weak momentum, RSI 31
RSI-14: 31.0 · SMA20: $2.99 · SMA50: $3.13
ESPR NASDAQ Head-to-Head Winner
Esperion Therapeutics, Inc.
Pharmaceutical Preparations
$3.18
-0.31% 1D
Market Cap $822.0M
TTM Revenue $418M
Forward P/E 10.9x
Beta / 30D Vol 1.86β · 6% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 64.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.5% over 20 days), RSI 64
RSI-14: 63.5 · SMA20: $3.16 · SMA50: $3.10

6-Pillar Scorecard Institutional Category Breakdown (SIGA 1 – 5 ESPR)

Columns: Metric · SIGA · ESPR
1. Valuation Multiples SIGA
Forward P/E 2.3x 10.9x
Trailing P/E N/M 4.6x
PEG Ratio 3.37x N/M
EV / Revenue 1.4x 2.2x
2. Growth & Scale ESPR
Revenue Growth (YoY) -49.7% +23.2%
Earnings Growth (YoY) -65.3% +0.0%
TTM Revenue (USD) $52M $418M
Market Cap $188.3M $822.0M
3. Profitability & Quality ESPR
Gross Margin 23.4% 57.8%
Operating Margin -14.2% -8.2%
Net Profit Margin 1.3% -1.8%
Return on Equity (ROE) 0.4% -260.8%
4. Balance Sheet & Cash Flow ESPR
Cash Generation (TTM) -$12M -$18M
Cash Flow Margin -22.1% -4.4%
Net Cash / Leverage $116M Net Cash $96M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ESPR
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 94.8% (6th %ile) 12.5% (9th %ile)
Put/Call OI Skew 0.50x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat ESPR
OpEx & R&D Intensity 37.6% of Rev ($20M) 66.0% of Rev ($276M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SIGA (3) vs ESPR (7)
Institutional Metric SIGA ESPR Criterion Row Edge
Market Capitalization
Scale
$188.3M $822.0M Larger Scale ESPR
Trailing P/E Ratio
Valuation
N/M 4.6x Lower Multiple ESPR
Forward P/E Ratio
Valuation
2.3x 10.9x Lower Multiple SIGA
Revenue Growth (YoY)
Growth
-49.7% +23.2% Higher Growth ESPR
Operating Margin (TTM)
Profitability
-14.2% -8.2% Higher Margin ESPR
Net Profit Margin
Profitability
1.3% -1.8% Higher Margin SIGA
Return on Equity (ROE)
Capital Efficiency
0.4% -260.8% Higher ROE SIGA
52-Week Range Position
Momentum
2% ($2–$7) 68% ($1–$4) Stronger Trend ESPR
Beta / 30D Volatility
Risk Regime
0.90β · 74% Vol 1.86β · 6% Vol Lower Realized Risk ESPR
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 60.0 / 100 (BUY) Higher Composite ESPR
Trailing 12M Revenue (USD)
Operating Scale
$52M $418M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.4% 57.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.37x PEG · 1.4x EV/Rev N/M PEG · 2.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M ($116M Net Cash) -$18M ($96M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ESPR +19.49 pp
SIGA: -18.22% · ESPR: +1.27%
3M Horizon ESPR +64.28 pp
SIGA: -18.41% · ESPR: +45.87%
6M Horizon ESPR +30.4 pp
SIGA: -47.59% · ESPR: -17.19%
1Y Horizon ESPR +53.24 pp
SIGA: -39.26% · ESPR: +13.98%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SIGA Revenue ESPR Revenue SIGA Op. Margin ESPR Op. Margin Margin Leader
FY2018 $480M N/A 74.4% N/A SIGA
FY2019 $30M $150M -8.7% -62.8% SIGA
FY2020 $120M $230M 67.6% -53.3% SIGA
FY2021 $130M $80M 66.7% -289.0% SIGA
FY2022 $110M $80M 38.5% -237.8% SIGA
FY2023 $140M $120M 59.8% -133.7% SIGA
FY2024 $140M $330M 50.4% 16.4% SIGA
FY2025 $90M $400M 25.1% 15.0% SIGA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SIGA BREAKDOWN
34d in phase · OBV DISTRIBUTION
Current IV 94.8%
IV Percentile 6th %ile
Put/Call OI Skew 0.50x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIGA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ESPR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 12.5%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ESPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SIGA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $188.3M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($20M)
90D Engineering Disclosures 0 Published
ESPR Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $822.0M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment 66.0% of Rev ($276M)
90D Engineering Disclosures 0 Published

Investor FAQ SIGA vs ESPR Key Questions & Quantitative Answers

As of Nov 20, 2026, Esperion Therapeutics, Inc. (ESPR) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SIGA carries a Unified Composite Score of 46.2/100 (HOLD) at $2.40 (2.3x Forward P/E, -14.2% operating margin), whereas ESPR carries 60.0/100 (BUY) at $3.18 (10.9x Forward P/E, -8.2% operating margin). Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.0); meanwhile ESPR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ESPR leads the Growth & Scale pillar: SIGA posts -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin), compared with ESPR at +23.2% YoY revenue growth and +0.0% YoY earnings growth on $418M TTM revenue (57.8% gross margin, -8.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SIGA cumulative revenue shifted -81.2% while ESPR shifted +166.7%. In operating R&D and SG&A reinvestment, SIGA deploys 37.6% of Rev ($20M) (0 90-day corporate R&D disclosures) versus 66.0% of Rev ($276M) (0 disclosures) for ESPR.

SIGA screens cheaper on headline valuation multiples. SIGA trades at 2.3x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin), whereas ESPR trades at 10.9x Forward P/E, 4.6x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (-4.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SIGA (0.4% ROE) versus ESPR (-260.8% ROE) capital efficiency.

In options market volatility and institutional positioning, SIGA carries 94.8% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.50x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.90β · 74% Vol realized risk). By comparison, ESPR carries 12.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.86β · 6% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.